Aktis Oncology (AKTS) vs Seaport Therapeutics (SPTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aktis Oncology is the larger company by market cap ($986.7 million vs $958.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | SPTX |
|---|---|---|
| Share price | $17.74 | $17.91 |
| Market cap | $986.69M | $958.73M |
| 1-day change | -1.44% | -0.11% |
| EPS (TTM) | $-1.70 | $-5.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $28.38 |
| 52-week low | $14.72 | $14.85 |
| Distance from 52-week high | -48.11% | -36.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.49% | +113.79% |
| Average volume | 364.04K | 182.18K |
| Shares outstanding | 53.75M | 53.53M |
| Employees | 79 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Seaport Therapeutics
SPTX stock →Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
AKTS vs SPTX FAQ
Which is bigger, Aktis Oncology or Seaport Therapeutics?
Aktis Oncology (AKTS) is larger, with a market capitalization of $986.69M compared with $958.73M for Seaport Therapeutics (SPTX).
Are Aktis Oncology and Seaport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.